T cell apoptosis characterizes severe Covid-19 disease

The study titled “T cell apoptosis characterizes severe Covid-19 disease” investigated the mechanisms behind lymphopenia in severe SARS-CoV-2 infections, focusing on the role of T cell apoptosis.

Here’s a detailed summary:

Study Overview

  • Context: Severe COVID-19 infections often result in lymphopenia (decreased lymphocyte count), but the underlying mechanisms remained unclear. The researchers hypothesized that like HIV, SARS-CoV-2 could induce T cell apoptosis (programmed cell death), contributing to lymphopenia​​.

Key Findings

  1. Increased sFasL and Fas Expression: Intensive Care Unit (ICU) and non-ICU COVID-19 patients showed significantly lower CD4 and CD8 T cell counts compared to healthy donors. Elevated CD95/Fas expression on memory T cells and increased plasma levels of soluble FasL (sFasL) were found, correlating positively with T cell death and negatively with T cell counts​​.
  2. Caspase Activity and T Cell Death: COVID-19 patients exhibited higher caspase activity in T cells than healthy donors. This heightened activity was closely associated with increased levels of sFasL and the frequency of memory T cells expressing CD95/Fas​​.
  3. Correlation with CXCL10 and Disease Severity: The study found a strong correlation between T cell apoptosis and CXCL10, a marker of inflammation and disease severity. Elevated levels of CXCL10, along with IL-1Ra, hepatocyte growth factor (HGF), and soluble CD14 (sCD14), were identified as biomarkers distinguishing ICU patients from healthy donors​​.
  4. Q-VD Prevents T Cell Apoptosis: The pan-caspase inhibitor Q-VD effectively inhibited caspase activity and apoptosis in T cells from COVID-19 patients. It was more effective than other tested inhibitors and also enhanced Th1 transcripts (IFN-γ and TNF-α), indicating restored T cell functionality. This suggests that blocking caspase activation might be a beneficial strategy in treating severe COVID-19 by preventing lymphopenia and improving immune response​​.

Conclusions The study demonstrated that in severe COVID-19, T cells are more prone to apoptosis, leading to lymphopenia and potentially exacerbating the disease severity. The pan-caspase inhibitor Q-VD, by preventing T cell apoptosis, could offer a new therapeutic strategy to improve immune cell survival and potentially reduce the severity and fatal outcomes in COVID-19 patients. This finding adds an important dimension to understanding the pathophysiology of severe COVID-19 and offers a potential avenue for therapeutic intervention.

Read More: https://www.nature.com/articles/s41418-022-00936-x

Leave a comment